Equities analysts expect that Dynavax Technologies Co. (NASDAQ:DVAX) will announce sales of $37.77 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Dynavax Technologies’ earnings. The lowest sales estimate is $530,000.00 and the highest is $75.00 million. Dynavax Technologies posted sales of $7.29 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 418.1%. The firm is expected to issue its next quarterly earnings results on Monday, March 12th.

According to Zacks, analysts expect that Dynavax Technologies will report full year sales of $37.77 million for the current fiscal year, with estimates ranging from $1.31 million to $75.31 million. For the next fiscal year, analysts anticipate that the company will report sales of $45.40 million per share, with estimates ranging from $39.78 million to $51.01 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.15. The business had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The company’s revenue was down 68.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.90) EPS.

A number of equities analysts have recently commented on DVAX shares. Royal Bank of Canada reaffirmed a “buy” rating and issued a $26.00 target price on shares of Dynavax Technologies in a report on Friday, September 1st. ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Cantor Fitzgerald started coverage on shares of Dynavax Technologies in a report on Friday, September 15th. They issued an “overweight” rating and a $24.00 target price on the stock. Cowen reaffirmed a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a report on Friday, November 3rd. Finally, BidaskClub cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $25.17.

Shares of Dynavax Technologies (DVAX) traded up $0.50 during trading on Friday, hitting $18.80. 1,153,773 shares of the stock were exchanged, compared to its average volume of 1,910,000. The firm has a market cap of $1,170.00, a PE ratio of -9.59 and a beta of 1.31. Dynavax Technologies has a fifty-two week low of $3.70 and a fifty-two week high of $24.45.

In other Dynavax Technologies news, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total value of $141,750.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 2.90% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC increased its stake in Dynavax Technologies by 54.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC increased its stake in Dynavax Technologies by 16.5% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 1,700 shares during the period. Bank of America Corp DE increased its stake in Dynavax Technologies by 2.3% in the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 456 shares during the period. Legal & General Group Plc increased its stake in Dynavax Technologies by 18.5% in the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 1,950 shares during the period. Finally, Wall Street Access Asset Management LLC acquired a new position in Dynavax Technologies in the 2nd quarter valued at $124,000. 70.54% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://theolympiareport.com/2017/12/23/zacks-brokerages-anticipate-dynavax-technologies-co-dvax-will-post-quarterly-sales-of-37-77-million.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.